GeneDx Holdings Corp

WGS is in a Stage 3 distribution phase with a bearish medium-term bias reinforced by a double top and failed breakout above prior highs. Price is currently tracking above the 9/21 EMA and 50 DMA cluster with no clear rejection, so immediate shorting is premature. Look to trim exposure into rebounds toward the EMA and 50 DMA zone. The long-term uptrend remains intact but is overshadowed by near-term distribution risks.

• ↑Test volume surged 34% YoY to 27,488 in Q1.
• ↑Q1 revenue $102.3M (+17% YoY) with avg reimbursement ~$3,700/test.
• ↓$31.2M impairment led to multiple securities class-action lawsuits.